MedPath

Treatment of Periodontitis by Conventional 4 Weekly Sections or Within 24 Hours

Phase 4
Completed
Conditions
Periodontitis
Interventions
Procedure: FMS full-mouth scaling
Procedure: QS quadrant scaling
Drug: QS placebo rinse
Drug: FMS placebo tablets
Drug: FMS placebo rinse
Drug: QS placebo tablets
Registration Number
NCT02215460
Lead Sponsor
University of Taubate
Brief Summary

Periodontitis is a form of gum disease that affects many people in the world. Its traditional protocol of treatment includes oral hygiene instruction and dental scaling to remove debris, dental plaque and tartar in 4 weekly sections. There is an additional time-reduced option also usually cheaper. In this last one, all above described procedures are performed within 24 hours. However, up to now comparative effectiveness between these both types of treatment is not well understood. For, example it is not clear if patients treated in the shorter-time experienced more pain. Therefore, the present study used several parameters to clarify whether beneficial differences between these therapeutic protocols exist or not. In addition, aspects that could help clinicians' and patient's decisions such as experience of pain and anxiety related to dental treatment were also investigated. After receiving verbal and written explanations and signed the informed consent form 150 individuals (n=15/group) having the most common type of periodontitis in adults were randomly allocated to be treated in 4 weekly sections or within 24 hours. Oral hygiene instructions and dental debridement were performed alone or in conjunction with antimicrobial agents: a mouth rinse containing chlorhexidine or systemic azithromycin antibiotic tablets. The parameters measured at baseline, 3, 6 and 9 months after treatment were: indicators of inflammation, amount of oral debris and malodor; quantification of bacteria in plaque samples collected with paper points from teeth and tongue; amount of produced saliva and self-reported questionnaires to collect information about oral condition, daily activities, pain and anxiety related to dental treatment.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
130
Inclusion Criteria
  • mild to moderate chronic periodontitis;
  • at least 20 natural teeth;
  • good general health
Exclusion Criteria
  • systemic diseases or other conditions that could influence the periodontal status;
  • events of high blood pressure or diagnosed hypertension;
  • alcohol abuse;
  • orthodontic devices;
  • extended prosthetic fixed devices, removable partial dentures or overhanging restorations;
  • pregnancy or breast-feeding;
  • history of sensitivity or suspected allergies following the use of oral hygiene products and/or the test antibiotic;
  • the need for antibiotic prophylaxis;
  • antibiotics and/or anti-inflammatory drug use in the three months prior to the beginning of the study;
  • regular use of chemotherapeutic antiplaque/antigingivitis products;
  • any furcation lesions;
  • periodontal treatment performed within six months prior to study initiation;
  • unwillingness to return for follow-up.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
FMS chlorhexidine rinseFMS full-mouth scaling-
FMS azithromycin tabletsFMS full-mouth scaling-
FMS azithromycin tabletsFMS azithromycin tablets-
FMS chlorhexidine rinseFMS chlorhexidine rinse-
Full-mouth scaling (FMS)FMS full-mouth scaling-
QS placebo rinseQS placebo rinse-
Quadrant scaling (QS)QS quadrant scaling-
QS chlorhexidine rinseQS chlorhexidine rinse-
FMS placebo tabletsFMS placebo tablets-
FMS placebo rinseFMS full-mouth scaling-
FMS placebo rinseFMS placebo rinse-
QS chlorhexidine rinseQS quadrant scaling-
QS placebo tabletsQS placebo tablets-
QS azithromycin tabletsQS quadrant scaling-
QS azithromycin tabletsQS azithromycin tablets-
QS placebo tabletsQS quadrant scaling-
FMS placebo tabletsFMS full-mouth scaling-
QS placebo rinseQS quadrant scaling-
Primary Outcome Measures
NameTimeMethod
Improvements in pocket depth and clinical attachment level measurementsChanges in pocket depth and clinical attachment level measurements from baseline to 6 months

Primary outcomes of effectiveness were improvements of the following clinical parameters: periodontal pocket depth (mm) and clinical attachment level (mm) from baseline to 6 months.

Secondary Outcome Measures
NameTimeMethod
Changes in volume of gingival crevicular fluid and levels of pro-inflammatory cytokines3 months

Possible reductions in gingival crevicular fluid volume and in concentrations of tumor necrosis factor alfa (TNFα) and interleukin 1 beta (IL-1β) were measured by comparing values between baseline and 3 months.

Changes in total bacterial load and levels of selected pathogens3 months

Reductions in total bacterial load and levels of selected pathogens were determined by real time PCR (polymerase chain reaction) in samples from periodontal pockets and dorsal tongue. Values between baseline and 3 months were compared.

Improvements in plaque index and gingival indexChanges from baseline to 3 months

Improvements in plaque index (scores) and gingival index (scores) when baseline data was compared to 3 months data.

Maintenance of pocket depth and clinical attachment level measurementsChanges in pocket depth and clinical attachment level from 6 months to 9 months

Pocket depth (mm) and clinical attachment level (mm) values observed at 6 were compared to those observed at 9 months.

Trial Locations

Locations (1)

Nucleus of periodontal research of University of Taubate

🇧🇷

Taubate, SP, Brazil

© Copyright 2025. All Rights Reserved by MedPath